INTRODUCTION
============

Despite surgical outcome has improved over the past few decades, pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies. After introduction of effective chemotherapeutic agents, the role of chemotherapy in both the adjuvant and neoadjuvant settings, becomes more important than ever. Gemcitabine (2',2'-difluorodeoxycytidine) is a standard chemotherapeutic agent in the treatment of both localized and metastatic PDACs in Korea. However, when administered in unselected patient populations, gemcitabine only showed a modest benefit in terms of survival. Therefore, better identification of patients who would benefit from administration of gemticibine is required. [@ref1]

As part of efforts to identify predictive biomarkers that forecast the likely response to gemcitabine of PDAC, several studies have investigated the relationship between the chemosensitivity of gemcitabine and integral membrane transporter proteins including human equilibrative nucleoside transporter 1 (hENT1).[@ref2],[@ref3] It was demonstrated that the deficiency in hENT1 was highly associated with the resistant effect of gemcitabine.[@ref4],[@ref5] As a prodrug, intracellular gemcitabine must be phosphorylated by deoxycytidine kinase (dCK) to its mononucleotide in the rate-limiting step of its cellular anabolism.[@ref6] Gemcitabine monophosphate then converts to its active forms, gemcitabine diphosphate and gemcitabine triphosphate.[@ref7] The cytotoxicity of gemcitabine is due to its blocking de novo DNA synthesis through inhibition of ribonucleotide reductase, which blocks production of the deoxyribonucleotide precursors required for DNA synthesis.[@ref6] Ribonucleotide reductase (RR) is a dimeric enzyme composed of a regulatory subunit M1 and a catalytic subunit M2.

While, hENT1, dCK, and RRM1 are important determinants of gemcitabine activity, about the prognostic and predictive values of immunohistochemical assessment of hENT1, dCK, and RRM1 in pancreatic cancer remain unclear, especially in Korean populations.[@ref8][@ref9]-[@ref10] In the present study, we aimed to investigate the correlation between key molecules (hENT1, dCK, RRM1 and RRM2) and 5-year actual survival in patients with PDAC.

MATERIALS AND METHODS
=====================

Study population
----------------

This case-control study was conducted in 200 consecutive and unselected patients with pathologically proven PDAC who underwent curative intent surgery from June 2003 through May 2012 at the Department of Surgery, Seoul National University Bundang Hospital, Korea. Tissue microarrays (TMAs) were made from archived tumor specimen, and 35 patients were excluded because of absence of tumor specimen. After excluding five more patients whose survival status could not be identified as of August 2019, 160 patients were finally enrolled in this study.

Data collection
---------------

Demographic, clinical, and pathological data were collected by an independent reviewer who was masked from the biomarker assessment results. The database was constructed with sex, age at surgery, tumor site, type of operation, tumor stage according to the 8th edition of American Joint Committee on Cancer (AJCC) staging, histologic grade, maximal tumor size, adjuvant therapy, chemotherapeutic regimen, recurrence, disease-free survival, and 5-year actual survival.

Operative procedure
-------------------

All type of pancreatectomy were included, such as conventional pancreaticoduodenectomy, pylorus-preserving pancreaticoduodenectomy, distal pancreatectomy, total pancreatectomy, and other types of parenchymal-sparing pancreatectomy. Depends on tumor location, types of pancreatectomy were decided. All patients underwent more than standard lymphadenectomy. When preoperative imaging studies showed invasion into the portal vein, the attending surgeon decided whether to perform portal vein resection. Intraoperative frozen section examination was performed regularly on proximal or distal pancreatic resection margin.

Biomarker assessment
--------------------

An independent pathologist masked to clinicopathologic data and survival outcome of patients (E. Shin) reviewed hematoxylin and eosin-stained slides of each patient. Tissue microarrays (TMAs) were made by 2 mm sized core from formalin-fixed, paraffin-embedded tumor specimens.[@ref11] Immunohistochemical staining for hENT1 and dCK was performed using Anti-hENT1 rabbit polyclonal antibody (PAB2255, 1:120, Abnova, Taipei, Taiwan) and anti-dCK mouse monoclonal antibody (LS-C172855, 1:50, LSBio, Seattle, WA, USA).[@ref12],[@ref13]

RRM1 expression was evaluated with a polyclonal rabbit antibody against human RRM1 (ab81085, 1:100, Abcam, Cambridge, UK) and RRM2 with polyconal goat antibody against human RRM2 (SC-10846, 1:250, Santa Cruz Biotechnology, Dellas, TX, USA). 4-µm-thick sections were cut from each of the paraffin tissue blocks, mounted on positively charged slides. Immunohistochemical staining for hENT1, dCK and RRM2 was performed using Leica Bond-max autostainer (Leica Biosystem, Vista, CA). After undergoing heat epitope retrieval for 20 minutes in Epitomic retrieval solution 2 (pH 9.0) in the autostainer, the samples were incubated with individual primary antibodies for 15 minutes. Then sides were incubated with polymer for 8 minutes and subsequently treated with DAB substrate for 10 minutes. Treatment with Harris hematoxylin for 1 minute was performed for counterstain. Immunohistochemical staining for RRM2 was manually done. Briefly, antigen was retrieved by treating pH 9.0 Tris-EDTA buffer at 100°C for 20 minutes. Endogenous peroxidase activity was blocked using 3% hydrogen peroxide for 6 minutes. For protein blocking, slides were incutaed in 5% normal horse serum for 30 minutes at room temperature. The primary antibody and the antibody binding were detected using an avidin-biotin complex reagent (Vector Lab., Burlingame, CA, USA) for 30 minutes and DAB substrate kit (Vector Lab., Burlingame, CA, USA) for 2 minutes.

The results of immunohistochemical staining was evaluated at ×200 magnificaion under a light microscope. The intensity staining was semi-quantitavely scored as scored as follows: grade 0, not stained; grade 1, equivocally stained; grade 2, weakly stained; grade 3, moderately stained; and grade 4, stained strongly. Islet cells, plasma and stromal cells were used as internal control. Additionally, the percentage of immune-reactive cells was assessed. For evaluation of intratumoral hENT1 expression, if grade 4 staining was observed in the neoplasms, the sample was considered to have high hENT1 expression, and if grade 0 to 3 staining was observed, the sample was considered to have low hENT1 expression. [@ref14]

Survival
--------

All patients were followed regularly in outpatient clinics with blood tests or imaging studies, including computed tomography (CT) every 3 to 6 months. Evaluation of recurrence was based on imaging studies. Final survival was assessed in at Aug. 2019 when all patients had achieved more than 5 years of follow-up. Survival information was collected by reviewing electrical medical records or telephone interview. For all patients, postoperative survival time, survival status, and recurrence status were reviewed and recorded.

Statistical analysis
--------------------

Statistical analysis was conducted using R 3.5.1. (R Foundation for Statistical Computing, Vienna, Austria). Categorical variables were reported as frequencies, and continuous variables were reported as median with range or mean with standard deviation, as appropriate. Categorical variables or proportions were compared using the chi-square test with continuity correction or Fisher's exact test. Continuous variables were compared using Student's t-test if normally distributed and the Wilcoxon rank-sum test otherwise. Survival curves were obtained using the Kaplan-Meier method. Log rank test and Cox proportional hazards models were used to compare overall survival. Tests of significance were undertaken at the two-tailed alpha level of 0.05. 

RESULTS
=======

Patients demographics and clinical data
---------------------------------------

Of the 160 patients, 93 (58.1%) were males and 67 (41.9%) were females; median age was 65 years (range, 40-89). Pancreatoduodenectomy, distal pancreatectomy, and total pancreatectomy were performed for 96 (60.0%), 54 (33.8%), and 6 (3.8%) patients, respectively. The proportion of patients with preoperative diabetes was significantly different between the two hENT1 intensity groups, with 30 (47.6%) and 28 (29.5%) patients, respectively (*p*=0.021). Pancreatic neoplasm were confined to the head and body/tail of the pancreas in 98 patients (62.5%) and 58 patients (36.3%), respectively. One hundred thirty seven patients (85.6%) underwent R0 resection.

According to TNM classification, 1 (0.6%), 3 (1.9%), and 150 (93.8%) patients had T1, T2, and T3 neoplasms, respectively; 97 patients (60.6%) had lymph node metastases. No patients had stage IA disease, whereas 3 (1.9%) patients had stage IB, 58 (36.3%) patients had stage IIA, 92 (57.5%) patients had stage IIB, and 7 (4.4%) patients had stage IV disease ([Table 1](#T1){ref-type="table"}).

Of 160 patients, 93 (58.1%) patients received adjuvant therapy. Among 93 patients, 70 received gemcitabine based adjuvant therapy. The proportion receiving adjuvant chemotherapy was not different between groups, with 46 (69.7%) and 47 (56.0%) patients, respectively (*p*=0.121). There was no significant difference with gemcitabine therapy (26 (41.3%) and 44 (45.4%) patients, *p*=0.729). High intratumoral expression of hENT1 was observed in 97 (60.6%) patients, and high hENT1 expression with gemcitabine therapy was identified in 44 (27.5%) patients.

DCK and RRM1 expression showed correlation with hENT1 expression, but, there was no significant correlation between RRM2 expression and hENT1 expression ([Table 1](#T1){ref-type="table"}).

Biomarker assessment and survival
---------------------------------

[Table 2](#T2){ref-type="table"} shows the results of analyses of predictive effects of various factors including immunohistochemical test results on overall survival. Age, sex, presence of preoperative diabetes and preoperative CA 19-9 level was not associated with overall survival. However, preoperative body mass index (BMI) and postoperative CA 19-9 level over 900 U/ml displayed significant interactive effects with overall survival (HR, 0.93; 95% confidence interval (CI), 0.88-0.98; *p*=0.007 and HR, 5.22; 95% CI, 2.33-11.68; *p*\<0.001). Tumor location, operation type, and extent of resection were not associated with survival. AJCC staging including T and N staging shows statistically significant interaction with overall survival.

Adjuvant chemotherapy including concurrent chemoradiotherapy was not associated with overall survival (HR, 0.92; 95% CI, 0.65-1.31; *p*=0.658). The intensity of hENT1 expression itself was not significantly associated with actual overall survival ([Table 2](#T2){ref-type="table"}, [Fig. 1](#F1){ref-type="fig"}). After grouping high hENT1 expression and others, there was no statistical survival difference (HR, 1.16; 95% CI, 0.82-1.65, *p*=0.396). To assess interactive effects of gemcitabine therapy, the group with gemcitabine therapy and high hENT1 expression was compared with all other patients, and no difference in overall survival was identified (HR, 0.99; 95% CI, 0.68-1.42; *p*=0.940). And, the group with gemcitabine therapy and high hENT1 expression was compared with gemcitabine therapy and low hENT1 expression, there was no statistical survival difference (HR, 0.92; 95% CI, 0.55-1.56; *p*=0.764) ([Fig. 2A](#F2){ref-type="fig"}). The comparison between gemcitabine with high hENT1 expression group and other chemotherapy with low hENT1 did not show significant survival difference ([Fig. 2B](#F2){ref-type="fig"}).

Similarly, the intensity of DCK, RRM1, and RRM2 expression was not associated with overall survival (*p*=0.413, *p*=0.138 and *p*=0.061) in univariate analysis ([Table 2](#T2){ref-type="table"}).

DISCUSSION
==========

In this study, we investigated the expression of hENT1, DCK, RRM1 and RRM2 by immunohistochemical analysis to determine their prognostic value in patients with pancreatic cancer. The results showed no significant relationship between protein expression and overall survival. Intratumoral hENT1 expression itself was not a prognostic factor for survival, and high hENT1 expression with gemcitabine therapy was not associated with survival after pancreatic cancer surgery. Moreover, expression of DCK, RRM1, and RRM2 had no correlation with survival.

Although combination chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival than gemcitabine therapy, gemcitabine still plays an important role in systemic chemotherapy for pancreatic cancer.[@ref15] Survival rate improves significantly with FOLFIRINOX, but gemcitabine remains an option because of the high incidence of toxic effects with FORFIRINOX. There are many reports about adjuvant gemcitabine therapy and prognostic factors. The majority of these reports showed that gatekeepers for intracellular uptake of gemcitabine (hENT1) and metabolic regulators of gemcitabine after intracellular entry (dCK, RRM1, and RRM2) are strongly associated with disease- free and overall survival in pancreatic cancer. [@ref6],[@ref14],[@ref16][@ref17]-[@ref18]

Our results are not in line with the results of previous reports investigating the prognostic and predictive value of these proteins in pancreatic cancer. First, we analyzed the prognostic value of hENT1 itself, whether or not gemcitabine was used because most previous studies reported an association between hENT1 and survival without analyzing the survival impact of hENT1 expression alone. The intensity of hENT1 expression did not show any correlation with survival, even in the high hENT1 expression group (*p*=0.398). We then investigated whether survival impact was enhanced when gemcitabine was used in patients with high hENT1. Survival of the group with high hENT1 and gemcitabine was not significantly different, compared with all other patients (HR, 0.986; 95% CI, 0.68-1.42; *p*=0.940). And, even in patients with gemcitabine adjuvant therapy, the survival of the group with high hENT1 did not show the statistical survival difference, compared with low hENT1 (HR, 0.92; 95% CI, 0.55-1.56; *p*=0.764). Expression of dCK also did not show any association with survival, unlike in previous studies.[@ref6],[@ref14],[@ref17] According to known intracellular mechanism and previous reports, RRM1 and RRM2 show reverse correlation with the effect of hENT1. However, in our results, RRM1 and RRM2 were not associated with overall survival. Although RRM2 showed marginal significance with survival by Cox proportional hazard ratio, the association was not proven by Kaplan-Meier survival curve.

This study may have had different results than the majority of previous studies for two main reasons. The first is the actual length of follow-up. If follow-up is less than 5 years, then 5-year overall survival may be overestimated compared to actual survival. The second consideration is the size of the study population. Except for a few large scale studies, most previous studies were conducted with small study populations, which affects the association and interpretation of results.[@ref6],[@ref17][@ref18]-[@ref19]

Our study had several limitations. First, this is a case-control study. A nonrandomized observational study should be interpreted with caution because of the potential for bias, especially selection bias. Second, a long study period would affect the outcome. A 10 year study period might coincide with major improvements in surgery, oncology, and general supportive care, which could mask the survival impact of gemcitabine related proteins. Third, inter-rater reliability was not measured. Measurement and selection biases should be avoided using all available methods.

Despite its limitations, this study suggests that expression of hENT1, dCK, RRM1 and RRM2 may not be associated with overall survival for patients with pancreatic cancer on gemcitabine adjuvant therapy. These proteins and other factors that may interact with or confound these results should be investigated in the near future. A well-designed cohort study with expression profiling of all available genes is required to create criteria regarding chemotherapeutic applications in patients with PDAC.
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![Kaplan-Meier survival curves. (A) Comparison of overall survival based on intensity of intratumoral hENT1 expression. There was no significant difference in overall survival. (B) High hENT1 expression group was compared with low hENT1 expression group, there was no statistical survival difference (HR, 1.16; 95% CI, 0.82-1.65, *p*=0.396). (C) When the group with gemcitabine therapy and high hENT1 expression was compared with all other patients, and no difference in overall survival was identified (HR, 0.99; 95% CI, 0.68-1.42; *p*=0.940).](AHBPS-24-127-f1){#F1}
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###### 

Comparison of clinicopathologic factors based on the intensity of intratumoral hENT1 expression

  Variables                                              Overall        hENT1 intensity   *p*-value      
  ------------------------------------------------------ -------------- ----------------- -------------- ---------
  Age (mean (SD), years)                                 64.61 (9.8)    66.30 (9.1)       63.50 (10.1)   0.077
  Sex                                                                                                    
  Male                                                   93 (58.1)      42 (66.7)         51 (52.1)      0.126
  Female                                                 67 (41.9)      21 (33.3)         46 (47.9)      
  Body Mass Index (mean, kg/m^2^)                        21.76 (3.33)   21.70 (3.00)      21.80 (3.55)   0.848
  Diabetes, preoperative                                                                                 
  Yes                                                    58 (36.7)      30 (47.6)         28 (29.5)      0.021
  No                                                     100 (63.3)     33 (52.4)         67 (70.5)      
  Preoperative CA19-9 (U/ml)                                                                             
  \<37                                                   46 (29.5)      15 (24.6)         31 (32.6)      0.322
  ≥37, \<300                                             56 (35.9)      22 (36.1)         34 (35.8)      
  ≥300, \<600                                            18 (11.5)      5 (8.2)           13 (13.7)      
  ≥600, \<900                                            7 (4.5)        4 (6.6)           3 (3.2)        
  ≥900                                                   29 (18.6)      15 (24.6)         14 (14.7)      
  Postoperative CA19-9 (U/ml)                                                                            
  \<37                                                   82 (54.7)      31 (50.0)         51 (58.0)      0.732
  ≥37, \<300                                             49 (32.7)      21 (33.9)         28 (31.8)      
  ≥300, \<600                                            9 (6.0)        5 (8.1)           4 (4.5)        
  ≥600, \<900                                            3 (2.0)        1 (1.6)           2 (2.3)        
  ≥900                                                   7 (4.7)        4 (6.5)           3 (3.4)        
  Location of tumor                                                                                      
  Head                                                   98 (62.0)      40 (62.5)         58 (60.4)      0.502
  Body                                                   20 (12.7)      6 (9.4)           14 (14.6)      
  Body and tail                                          8 (5.1)        2 (3.1)           6 (6.3)        
  Tail                                                   30 (19.0)      14 (21.9)         16 (16.7)      
  Whole pancreas                                         4 (2.5)        2 (3.1)           2 (2.1)        
  Type of operation                                                                                      
  Pancreaticoduodenectomy including pylorus-preserving   96 (60.0)      37 (58.7)         59 (60.8)      0.818
  Distal pancreatectomy                                  54 (33.8)      21 (33.3)         33 (34.0)      
  Total pancreatectomy                                   6 (3.8)        2 (3.2)           4 (4.1)        
  Others                                                 4 (2.5)        3 (4.8)           1 (1.0)        
  R0 resection                                                                                           
  Yes                                                    137 (85.6)     54 (84.4)         83 (86.5)      0.780
  No                                                     23 (14.4)      10 (15.6)         13 (13.5)      
  T stage                                                                                                
  T1                                                     1 (0.6)        0 (0.0)           1 (1.0)        0.593
  T2                                                     3 (1.9)        2 (3.2)           1 (1.0)        
  T3                                                     150 (93.8)     58 (92.1)         92 (94.8)      
  T4                                                     6 (3.8)        3 (4.8)           3 (3.1)        
  N stage                                                                                                
  N0                                                     62 (38.8)      20 (31.7)         42 (43.3)      0.227
  N1                                                     97 (60.6)      43 (68.3)         54 (55.7)      
  Nx                                                     1 (0.6)        0 (0.0)           1 (1.0)        
  M stage                                                                                                
  M0                                                     155 (96.9)     63 (100.0)        92 (94.8)      0.172
  M1                                                     5 (3.1)        0 (0.0)           5 (5.2)        
  Stage, AJCC 8th                                                                                        
  IB                                                     3 (1.9)        2 (3.2)           1 (1.0)        0.154
  IIA                                                    58 (36.2)      17 (27.0)         41 (42.3)      
  IIB                                                    92 (57.5)      42 (66.7)         50 (51.5)      
  IV                                                     7 (4.4)        2 (3.2)           5 (5.2)        
  Adjuvant therapy                                                                                       
  Yes                                                    93 (58.1)      46 (69.7)         47 (56.0)      0.121
  Chemotherapy, only                                     61             27                34             
  CCRT                                                   32             19                13             
  No                                                     57 (41.9)      20 (30.3)         37 (44.0)      
  Gemcitabine adjuvant therapy                                                                           
  Yes                                                    70 (43.8)      26 (41.3)         44 (45.4)      0.729
  No                                                     90 (56.2)      37 (58.7)         53 (54.6)      
  hENT1 (intensity)                                                                                      
  0                                                      5 (3.1)        5 (7.9)                          
  1                                                      9 (5.6)        9 (14.3)                         
  2                                                      10 (6.2)       10 (15.9)                        
  3                                                      39 (24.4)      39 (61.9)                        
  4                                                      97 (60.6)                        97 (100.0)     
  DCK (intensity)                                                                                        
  0                                                      48 (30.6)      33 (53.2)         15 (15.8)      \<0.001
  1                                                      0 (0.0)        0 (0.0)           0 (0.0)        
  2                                                      39 (24.8)      19 (30.6)         20 (21.1)      
  3                                                      64 (40.8)      10 (16.1)         54 (56.8)      
  4                                                      6 (3.8)        0 (0.0)           6 (6.3)        
  RRM1 (intensity)                                                                                       
  0                                                      25 (16.1)      21 (33.3)         4 (4.3)        \<0.001
  1                                                      15 (9.7)       7 (11.1)          8 (8.7)        
  2                                                      66 (42.6)      25 (39.7)         41 (44.6)      
  3                                                      43 (27.7)      8 (12.7)          35 (38.0)      
  4                                                      6 (3.9)        2 (3.2)           4 (4.3)        
  RRM2 (intensity)                                                                                       
  0                                                      16 (10.3)      8 (12.7)          8 (8.7)        0.150
  1                                                      0 (0.0)        0 (0.0)           0 (0.0)        
  2                                                      7 (4.5)        1 (1.6)           6 (6.5)        
  3                                                      62 (40.0)      30 (47.6)         32 (34.8)      
  4                                                      70 (45.2)      24 (38.1)         46 (50.0)      
  hENT1 high+gemcitabine                                 44 (27.5)      0 (0.0)           44 (45.4)      \<0.001
  Others                                                 116 (72.5)     63 (100.0)        53 (54.6)      

hENT1, human equilibrative nucleoside transporter 1; dCK, deoxycytidine kinase; RRM1, ribonucleotide reductase regulatory subunit M1; RRM2, ribonucleotide reductase regulatory subunit M2; AJCC, American Joint Committee on Cancer

###### 

Univariate overall survival analysis for 160 patients

  Variables                                                Univariate                     
  -------------------------------------------------------- ------------ ------- --------- ---------
  Age                                                      1.002        0.984   1.020     0.848
  Sex                                                      0.891        0.632   1.256     0.510
  BMI                                                      0.927        0.878   0.980     0.007
  Preoperative diabetes                                    1.010        0.705   1.447     0.957
  Preoperative CA 19-9 (reference, \<37 U/ml)                                             0.475
  ≥37, \<300                                               1.272        0.828   1.952     0.272
  ≥300, \<600                                              1.183        0.657   2.130     0.576
  ≥600, \<900                                              1.736        0.731   4.120     0.211
  ≥900                                                     1.529        0.923   2.531     0.099
  Postoperative CA 19-9 (reference, \<37 U/ml)                                            0.008
  ≥37, \<300                                               1.440        0.983   2.110     0.061
  ≥300, \<600                                              1.568        0.751   3.272     0.231
  ≥600, \<900                                              1.555        0.485   4.985     0.458
  ≥900                                                     5.222        2.335   11.68     \<0.001
  Location of tumor (reference, head)                                                     0.884
  Body                                                     0.970        0.407   2.308     0.944
  Body and tail                                            0.799        0.485   1.317     0.379
  Tail                                                     1.893        0.251   14.273    0.536
  Whole pancreas                                           0.591        0.079   4.427     0.609
  Type of operation (reference, pancreaticoduodenectomy)                                  0.235
  Distal pancreatectomy                                    2.454        0.563   10.694    0.232
  Total pancreatectomy                                     0.578        0.313   1.067     0.080
  Others                                                   0.389        0.113   1.345     0.136
  Extent of resection                                      1.013        0.531   1.934     0.968
  T stage                                                                                 0.025
  T2                                                       0.038        0.002   0.618     0.022
  T3                                                       0.159        0.021   1.174     0.071
  T4                                                       0.408        0.048   3.476     0.412
  N stage                                                                                 0.017
  N1                                                       1.421        1.004   2.009     0.047
  Nx                                                       27.920       3.388   230.051   0.002
  AJCC 8th stage (reference, stage IB)                                                    0.032
  IIA                                                      3.668        0.506   26.581    0.198
  IIB                                                      4.690        0.651   33.764    0.125
  IV                                                       9.351        1.146   76.266    0.037
  Adjuvant chemotherapy                                    0.923        0.649   1.314     0.658
  Gemcitabine adjuvant therapy                             1.006        0.719   1.409     0.971
  hENT1 (reference, intensity 0)                                                          0.398
  1                                                        0.347        0.105   1.149     0.083
  2                                                        0.647        0.217   1.935     0.436
  3                                                        0.629        0.244   1.622     0.338
  4                                                        0.698        0.283   1.722     0.435
  dCK (reference, intensity 0)                                                            0.413
  2                                                        1.253        0.795   1.976     0.331
  3                                                        0.956        0.635   1.437     0.828
  4                                                        0.612        0.218   1.714     0.350
  RRM1 (reference, intensity 0)                                                           0.138
  1                                                        0.793        0.387   1.626     0.527
  2                                                        1.337        0.803   2.225     0.264
  3                                                        0.907        0.523   1.572     0.728
  4                                                        0.565        0.193   1.656     0.298
  RRM2 (reference, intensity 0)                                                           0.048
  2                                                        0.475        0.155   1.458     0.193
  3                                                        0.951        0.517   1.749     0.872
  4                                                        1.375        0.757   2.499     0.296
  hENT1 high                                               1.163        0.821   1.648     0.396
  hENT1 high+gemcitabine                                   0.986        0.683   1.424     0.940

hENT1, human equilibrative nucleoside transporter 1; dCK, deoxycytidine kinase; RRM1, ribonucleotide reductase regulatory subunit M1; RRM2, ribonucleotide reductase regulatory subunit M2; AJCC, American Joint Committee on Cancer
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